News Sentiment

JBIO sentiment intelligence

Jade Biosciences, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 24 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 20.86 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

73/100 classification confidence.

Company focus 15

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-0.4% over one week, +24.0% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Price to sales forward of Jade Biosciences, Inc. – NASDAQ:JBIO

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 73/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend active 24.0% over four weeks
Fair value -88.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 17
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 15
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
TradingView 3
simplywall.st 3
Stock Titan 2
Insider Monkey 1
Quiver Quantitative 1
Seeking Alpha 1
Gotrade 1

Event Lens

What the news is about

Classified themes
Earnings 10
Market update 8
Deals and strategy 6

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-24 of 24
QuotedData Direct company coverage

RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics

Jade Biosciences, a portfolio company of RTW Biotech Opportunities (RTW), has merged with Nasdaq-listed Aerovate Therapeutics, with the combined entity retaining the Jade Biosciences name and JBIO ticker. This merger provides Jade Biosciences with a public listing and resources t

Tone
Positive 72/100
Event
Deals and strategy
Published
30 Apr 2025 09:09
Source
QuotedData
GlobeNewswire Direct company coverage

Jade Biosciences Completes Closing of Merger with Aerovate

Jade Biosciences announced the completion of its merger with Aerovate Therapeutics and an oversubscribed private investment round of approximately $300 million. The combined company, operating as Jade Biosciences, Inc., will trade on Nasdaq under "JBIO" and aims to advance best-i

Tone
Positive 71/100
Event
Deals and strategy
Published
28 Apr 2025 18:09
Source
GlobeNewswire
citybiz Direct company coverage

Aerovate Therapeutics and Jade Biosciences Merger Approved

Aerovate Therapeutics announced stockholder approval for its merger with Jade Biosciences, including a 1-for-35 reverse stock split. The combined company will trade on Nasdaq as "Jade Biosciences, Inc." (JBIO) starting April 29, 2025, with an estimated 32.2 million shares outstan

Tone
Positive 70/100
Event
Deals and strategy
Published
21 Apr 2025 04:09
Source
citybiz
Investing.com Nigeria Direct company coverage

Aerovate approves reverse split ahead of Jade merger By Investing.com

Aerovate Therapeutics, Inc. announced a 1-for-35 reverse stock split ahead of its merger with Jade Biosciences, Inc., with the combined company set to trade as "JBIO" on Nasdaq from April 29, 2025. Stockholders will also receive a special cash dividend of an estimated $2.40 per s

Tone
Positive 64/100
Event
Deals and strategy
Published
21 Apr 2025 02:09
Source
Investing.com Nigeria
qz.com Direct company coverage

Aerovate Therapeutics Inc. (AVTE) reports earnings

Aerovate Therapeutics Inc. (AVTE) filed its 10-K report for the fiscal year ended December 31, 2024, detailing a halt in the development of AV-101 due to negative clinical trial results. The company is undergoing restructuring and exploring a merger with Jade Biosciences, Inc., f

Tone
Neutral 50/100
Event
Deals and strategy
Published
27 Mar 2025 05:09
Source
qz.com